BeOne Medicines AG
ONC
#600
Rank
$42.511 B
Marketcap
Switzerland
Country
$375.80
Share price
4.60%
Change (1 day)
1.05%
Change (1 year)
Categories
BeOne Medicines AG, an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company's commercial stage products include BRUKINSA, a small molecule inhibitor of Bruton's Tyrosine Kinase (BTK) for the treatment of various blood cancers; TEVIMBRA, an anti-PD-1 antibody immunotherapy for the treatment of various solid…
Key Metrics
Trailing P/E
62.16
Forward P/E
33.74
EPS (TTM)
$5.60
Forward EPS
$10.32
Price / Book
7.60
EV / EBITDA
34.1x
Beta
0.52
Dividend Yield
—
Return on Equity
14.66%
Return on Assets
7.46%
Debt / Equity
39.61
Current Ratio
3.40
Gross Margin
88.89%
Operating Margin
19.06%
Net Profit Margin
10.70%
Free Cash Flow
$879.022M
Charts
Price history and financial performance over time.
Price & Market Cap
Aug 18 – Sep 16
-5.71%
Source: Yahoo Finance daily closes. Market cap uses the closest quarterly shares-outstanding filing for each date.
Revenue & Net Income
Annual · USD
RevenueNet Income
Latest Revenue$5.343B
Latest Net Income$286.933M
Reporting periods4
Source: Yahoo Finance annual income statements. Year is the fiscal-year end. Most recent period may be trailing-twelve-month (TTM) until the next 10-K is filed.
Compare BeOne Medicines AG with competitors
Side-by-side market cap, revenue, and financial comparison.
Latest News
Latest News
ONC
No recent news available. Set FINNHUB_API_KEY to enable news.
